These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6230463)

  • 1. Methotrexate in the treatment of metastatic and recurrent primary transitional cell carcinoma.
    Oliver RT; England HR; Risdon RA; Blandy JP
    J Urol; 1984 Mar; 131(3):483-5. PubMed ID: 6230463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate for superficial bladder cancer.
    Hall RR
    Prog Clin Biol Res; 1985; 185B():143-9. PubMed ID: 3898139
    [No Abstract]   [Full Text] [Related]  

  • 3. Methotrexate as salvage or adjunctive therapy for primary invasive carcinoma of the bladder.
    Oliver RT
    Cancer Treat Rep; 1981; 65 Suppl 1():179-81. PubMed ID: 6173120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic oral methotrexate therapy for multiple superficial bladder carcinoma.
    Hall RR; Herring DW; Gibb I; Heath AB
    Br J Urol; 1981 Dec; 53(6):582-4. PubMed ID: 7317746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Nb rat transitional cell bladder carcinoma model: dose response to methotrexate and adriamycin.
    Drago JR; Nesbitt JA
    Anticancer Res; 1986; 6(5):1019-20. PubMed ID: 3800312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate treatment for advanced bladder cancer.
    Hall RR; Bloom HJ; Freeman JE; Nawrocki A; Wallace DM
    Br J Urol; 1974 Aug; 46(4):431-8. PubMed ID: 4414661
    [No Abstract]   [Full Text] [Related]  

  • 8. [Adjuvant chemotherapy with biocisplatin, methotrexate and biocarbazine in advanced bladder tumors].
    Ormanov I; Kumanov Kh; Tsvetkov M
    Khirurgiia (Sofiia); 1989; 42(6):45-8. PubMed ID: 2634801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical methotrexate in the treatment of superficial bladder cancer.
    Smith G; Theodorou C; Field G; Hargreave TB; Chisholm GD
    Br J Urol; 1984 Dec; 56(6):663-7. PubMed ID: 6534486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of metastatic bladder cancer.
    Yagoda A
    Cancer; 1980 Apr; 45(7 Suppl):1879-88. PubMed ID: 7189443
    [No Abstract]   [Full Text] [Related]  

  • 11. Extended experience of neo-adjuvant M-VAC chemotherapy for T1-4 N0 M0 transitional cell carcinoma of the urinary bladder.
    Keating JP; Zincke H; Hahn RG; Morgan WR
    Prog Clin Biol Res; 1990; 353():119-27. PubMed ID: 2217409
    [No Abstract]   [Full Text] [Related]  

  • 12. [Low-grade, low-stage transitional carcinoma of the bladder. Analysis of 147 cases].
    Escudero Barrilero A; Gutiérrez Sanz-Gadea C; Hernández Fernández C; Mateos Torres A; Maganto Pavón E; Mayayo Dehesa T
    Actas Urol Esp; 1985; 9(2):135-46. PubMed ID: 3925729
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral methotrexate for superficial transitional cell carcinoma of the bladder.
    Olver IN; Sandeman TF; Laidlaw CR; Zimet AS; Bishop JF
    J Urol; 1993 May; 149(5):1006-9. PubMed ID: 8483200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate: an active drug in bladder cancer.
    Natale RB; Yagoda A; Watson RC; Whitmore WF; Blumenreich M; Braun DW
    Cancer; 1981 Mar; 47(6):1246-50. PubMed ID: 6971700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.
    Scher HI; Yagoda A; Herr HW; Sternberg CN; Bosl G; Morse MJ; Sogani PC; Watson RC; Dershaw DD; Reuter V
    J Urol; 1988 Mar; 139(3):470-4. PubMed ID: 3343728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cases of the regression of advanced bladder tumors (T2-T4) after the use of chemotherapy].
    Kumanov Kh; Ormanov I; Tsvetkov M; Donovski L; Panchev P
    Khirurgiia (Sofiia); 1990; 43(1):87-93. PubMed ID: 2395293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma.
    Garnick MB; Schade D; Israel M; Maxwell B; Richie JP
    J Urol; 1984 Jan; 131(1):43-6. PubMed ID: 6690745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningeal carcinomatosis from transitional cell carcinoma of the bladder.
    Eng C; Cunningham D; Quade BJ; Schwamm L; Kantoff PW; Skarin AT
    Cancer; 1993 Jul; 72(2):553-7. PubMed ID: 8319186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N; Weiselberg LR
    J Urol; 1988 Mar; 139(3):461-9. PubMed ID: 3343727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.